Thymol Derivatives from *Eupatorium fortunei*

Motoo Tori,* Yukiko Ohara, Katsuyuki Nakashima, and Masakazu Sono

Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan

Received March 1, 2001

Sixteen new thymol derivatives have been isolated from *Eupatorium fortunei* and their structures determined based on spectroscopic data. They were classified into three groups (i–iii) depending on the oxidation levels: (i) one oxygen function at the 9-position, (ii) two oxygen functions at the 8- and 9-positions, and (iii) three oxygen functions at the 8-, 9-, and 10-positions. The hydroxyl groups are acylated with tigloyl, angeloyl, acetyl, isobutyryl, 3-methyl-2-butenoyl, or 2-methylbutyryl moieties. The compounds having chiral centers showed no specific rotation and exist as racemic mixtures.

Eupatorium fortunei was once distributed in fields or at riversides in Japan; however, this species is now rarely found in the field. It has a pleasant odor when the stem is cut and has been called "a scent plant". There are some reports on the constituents of *E. fortunei*.¹ A Japanese group has reported the isolation of eupafortunin, a germacrane-type sesquiterpene,² and a Chinese group has found pyrrolizidine alkaloids.³ However, no other report on the isolation of thymol derivatives has appeared, but thymol derivatives have been found in other *Eupatorium* species.^{4–8} We have investigated the chemical constituents of Petasites,⁹ Farfugium,¹⁰ Eupatorium,¹¹ and other plants¹² classified to Compositae. In the present study the methanol extract of *E. fortunei* has been separated and the structures of the isolated compounds have been determined. Now we describe the details of this work.

Results and Discussion

A MeOH extract of the aerial parts of *E. fortunei* was separated into three fractions: an EtOAc-soluble fraction, a CHCl₃-soluble fraction, and an *n*-BuOH-soluble fraction. The EtOAc-soluble fraction was further purified by repeated silica gel column chromatography to yield 16 new compounds (1-16, Chart 1). The ¹³C assignments for 1-16are shown in Tables 1 and 2. Compounds **1–3** were tiglate¹³ derivatives of thymol. Compound **1** showed a peak at m/z231 as the largest value of m/z (CIMS), and the IR spectrum showed an absorption at 1740 cm⁻¹. The ¹H NMR spectrum exhibited the typical pattern of a 1,2,4-trisubstituted phenyl group, a proton characteristic of an α,β -unsaturated system, exomethylene protons, and four methyl groups attached to an aromatic ring and sp² carbons, respectively. Therefore, it was concluded that compound 1 was 8,9dehydrothymol 3-O-tiglate.

Compound **2** exhibited the presence of a tiglate,¹³ an acetate, and an exomethylene group. Two protons at δ 4.79 (s) had an HMBC correlation peak to the carbonyl group at δ 170.6 assignable to the acetate moiety. Therefore, and by comparison with the data of **1**, compound **2** was determined to be 9-acetoxy-8,10-dehydrothymol 3-*O*-tiglate. The NMR data of compound **3** resembled those of **2**, except that it had no exomethylene group. As it had a secondary methyl group instead, **3** was identified as 9-acetoxythymol 3-*O*-tiglate.

Compounds **4** and **5** had an epoxide at the 8,10-position. Compound **4** showed the presence of a tiglate,¹³ a primary

* To whom correspondence should be addressed. Tel: +81-88-622-9611 (ext. 5631). Fax: +81-88-655-3051. E-mail: tori@ph.bunri-u.ac.jp.

hydroxyl, and two proton signals at δ 3.18 and 2.81, each a doublet ($J=5.2~{\rm Hz}$) assigned to the 10-position of the epoxide. The tiglate moiety was obviously attached to the 3-hydroxyl group due to the chemical shifts of the protons at the 9-positions.

Compound **5** exhibited the presence of an angeloyl group.¹³ The proton at δ 6.28 (H-3') had NOEs into both methyl groups at δ 2.04 (dq, J = 1.5 and 1.5 Hz, H-5') and 2.07 (dq, J = 7.4 and 1.5 Hz, H-4'). There were only two aromatic proton signals at δ 6.89 (s) and 6.86 (d, J = 0.5 Hz), which indicated their *para* positioning. The HMBC spectrum did not indicate the position of the angeloyl group (either 3- or 6-position). Therefore, **5** was reacted with MOMCl to prepare the MOM derivative **5a** (Figure 1). The NOESY spectrum of **5a** clearly showed the proximity of the methylene group doublets at δ 5.17 and 5.21 to H-5 (δ 7.14).¹⁴ Further NOEs were detected between H-5 and H-10 and between H-2 and H-7, as in the case of compound **5**. Therefore, compound **5** was determined to be 9-acetoxy-8,10-epoxy-6-hydroxythymol 3-*O*-angelate.

Compound **6** has no methyl group attached to the aromatic ring, but the presence of a tertiary methyl group was indicated. The 1,2,4-trisubstituted pattern was indicated by the ¹H NMR spectrum. The HMBC spectrum suggested that the acetyl group was attached to the 7-position and the isobutyryl group to the 9-position. Therefore, **6** was determined to be 7-acetoxy-8-hydroxy-9-isobutyryloxythymol.

Compounds 7–13 had a methoxyl group at the 8-position. The position of the methoxyl group was determined by a HMBC long-range correlation peak between the methoxyl group and the carbon at the 8-position. Compound 7 was 8-methoxy-9-hydroxythymol, and compound 8 was a 3-*O*-isobutyryl derivative of 7. Compound 9 was a 3-*O*-tiglate derivative of 7, and compound 10 was a 3-*O*(3-methyl-2-butenoyl) derivative of 7. Compound 11 was assigned as a 9-*O*-angeloyl derivative of 7, and compound 12 was a 9-*O*-isobutyryl derivative of 7. Compound 13 showed the presence of a 2-methylbutyryloxy moiety attached to the 9-position and was a diastereomeric mixture. The structures of 7–13 were determined by analysis of the 2D NMR spectra.

Compounds **14** and **15** had three oxygen functions at the isopropyl group of thymol. Angeloyl and acetyl groups were detected for compound **14**, while there were a tigloyl and an acetyl group in compound **15**. The positions of these groups were determined by the 2D NMR spectra.

Compound **16** had a different skeleton. The NMR spectra showed the presence of a secondary hydroxyl [δ_H 5.17 (1H,





Table 1. ^{13}C NMR Spectral Data (δ) of Compounds 1–8 (100 MHz, in CDCl_3)

position	1	2	3	4	5	6	7	8
1	138.2	139.2	137.5	139.8	125.8	137.5	140.1	139.2
2	123.3	123.4	123.2	123.3	124.8	117.4	117.7	124.9
3	147.4	147.8	148.5	148.5	141.3	156.5	156.0	149.0
4	133.6	129.7	131.8	126.7	127.2	125.7	127.8.	129.8
5	129.0	129.7	127.1	128.8	114.7	126.4	121.1	129.0
6	126.6	126.7	127.0	126.9	151.7	119.0	120.8	126.6
7	21.0	21.1	20.9	21.1	15.8	65.6	21.0	20.7
8	141.6	140.5	31.9	59.2	56.7	77.6	83.1	79.4
9	115.5	66.3	68.6	63.2	65.4	70.5	68.7	68.9
10	23.5	117.2	17.4	50.2	51.2	25.9	19.2	20.1
1′	166.3	166.1	166.2	166.0	166.2	177.6		175.6
2'	127.4	127.1	127.1	126.6	126.7	33.9		34.3
3′	140.1	140.7	140.9	141.5	141.4	18.9		18.8
4'	15.9	15.9	16.0	16.0	16.0	18.9		18.8
5'	20.6	20.6	20.9	20.7	20.7			
CH_3CO		170.6	171.0		170.0	170.8		
CH ₃ CO		20.9	20.9		20.7	21.0		
OMe							50.7	50.8

s); δ_C 78.8 (CH)], an acetyl [δ_H 2.11 (3H, s); δ_C 21.2 (CH₃) and 207.4], and a methyl group [δ 2.30 (s)] attached to the aromatic ring. The substitution pattern of the aromatic ring was the same as that of thymol. Therefore, it was concluded that compound **16** is 2-(1'-hydroxy-2'-oxopropyl)-5-meth-ylphenol.

Interestingly compounds having a methoxyl group at the 8-position showed no specific rotation, except for 10. Analysis using a chiral HPLC column (Chiralcel OD-H) revealed that 7–9 and 11–13 exist as racemic mixtures, while compound 10 showed only one peak under the same conditions. Therefore, we suspect that these may be artifacts formed during the isolation using methanol. However, the absolute configurations of compound 10 and other compounds having chiral centers have not been determined yet. Some thymol derivatives isolated from *E. stoechadosmum* showed no optical rotation, although they had chiral centers.⁸ Furukawa and his group also reported that eupatriol had no optical rotation.⁷



Table 2. ^{13}C NMR Spectral Data (δ) of Compounds $9{-16}$ (in $\text{CDCl}_3)$

position	9 ^a	10 ^a	11 ^b	12 ^b	13 ^a	14 ^b	15 ^b	16 ^b
1	139.1	138.9	140.1	140.0	140.1	140.1	139.4	140.7
2	125.1	125.1	117.8	120.6	117.8	118.6	124.4	118.0
3	148.6	148.4	156.1	156.1	156.1	156.6	147.4	154.9
4	130.0	130.1	121.0	120.8	120.7	118.9	128.7	119.2
5	129.0	128.8	127.5	127.4	127.4	126.3	128.6	129.3
6	126.7	126.6	120.7	117.7	120.7	120.5	126.9	121.7
7	20.8	20.8	21.0	20.2	21.0	20.9	20.8	25.0
8	79.4	79.5	81.2	81.2	81.3	78.5	76.2	78.8
9	69.1	69.1	68.2	68.4	68.3 ^c	67.3	68.2	207.4
10	20.2	20.4	20.6	18.9	20.3	67.6	66.4	21.2
1′	166.4	165.1	167.4	176.5	176.2	168.1	166.5	
2'	127.1	115.2	127.5	33.9	41.0	126.9	126.7	
3'	141.1	160.3	138.6	18.8	26.6^{d}	140.2	142.2	
4'	15.9	27.7	15.7	18.8	11.5	15.8	16.0	
5'	20.7	20.5	20.6		16.5	20.4	20.6	
CH_3CO						171.2	171.6	
CH ₃ CO						20.7	20.7	
OMe	50.9	50.9	50.8	50.8	50.8			

 a 150 MHz. b 100 MHz. (Signals due to the presence of the distereoisomer. c 68.2. d 26.7).



Figure 1. Methoxymethylation of compound 5 and the NOEs observed for 5a.

Experimental Section

General Experimental Procedures. The IR spectra were measured with a JASCO FT/IR-5300 spectrophotometer. The ¹H, ¹³C, and 2D NMR spectra were taken with a Varian Unity 600 (600 MHz), a JEOL GX400 (400 MHz), or a Varian Unity 200 (200 MHz) spectrometer. The mass spectra including highresolution mass spectra were taken with a JEOL JMS AX-500 spectrometer. GC–MS was measured with a HP GC6890-MS5973 system. Specific rotations were measured with a JASCO DIP-140. Chemcopak Nucleosil 50-5 and Chiralcel OD-H (Daisel) were used for HPLC (JASCO pump system). Silica gel 60 (70–230 mesh, Merck) was used for column chromatography, and silica gel 60 F_{254} plates (Merck) were used for TLC.

Plant Material. *E. fortunei* was cultivated in a garden in Tokushima City for five years (1994–1998). A voucher specimen (TBU-MT-199501) is deposited at the Herbarium of the Faculty of Pharmaceutical Sciences, Tokushima Bunri University. The plant was identified by Dr. Takayuki Kawahara, Hokkaido Research Center of Forestry and Forest Products Research Institute, Ministry of Agriculture, Forestry and Fisheries, Japan.

Extraction and Isolation. The methanol extract (161.2 g) of the aerial parts (half-dried, 1.29 kg) was partitioned between EtOAc, CHCl₃, and then *n*-BuOH, successively. The EtOAc-soluble fraction (48.95 g) was subjected to silica gel column chromatography and was eluted by hexane-AcOEt, followed by CHCl₃-MeOH, in gradient, Sephadex LH-20 $(CHCl_3-MeOH = 1:1)$, and then HPLC (hexane-EtOAc or CHCl₃-EtOAc) to give 28 compounds: 1 (6.6 mg), 2 (72.0 mg), 3 (58.2 mg), 4 (20.9 mg), 5 (6.7 mg), 6 (2.1 mg), 7 (15.7 mg), 8 (17.5 mg), 9 (2.23 g), 10 (5.7 mg), 11 (22.4 mg), 12 (470.9 mg), 13 (4.8 mg), 14 (12.3 mg), 15 (28.0 mg), 16 (7.3 mg), (3S,4S)-3-hydroxy-p-menth-1-ene-6-one (1.3 mg),¹⁵ thymol (3.2 mg),⁴ thymol methyl ether (7.7 mg),⁴ hydrothymoquinone dimethyl ether (10.3 mg),¹⁶ thymol 3-O-tiglate (9 mg), thymol 3-O-(2methylpropionate) (9.7 mg),4 8,9-dehydrothymol 3-O-(2-methylpropionate) (4.3 mg),⁴ 9-hydroxy-8,10-dehydrothymol (9.5 mg),¹⁵ 9-hydroxythymol (5.8 mg),¹⁵ 8,9-dihydroxythymol (35.8 mg),⁷ 9-acetoxy-8,10-epoxythymol 3-O-tiglate (324.9 mg),¹⁷ and caryophyllene oxide (10.1 mg).18

1: IR (KBr) ν_{max} 1740, 1650, 1630 cm⁻¹; CIMS *m/z* 231 [M + H]⁺, 213, 186, 149, 83 (100); ¹H NMR (CDCl₃, 400 MHz) δ 2.02 (3H, s, H-10), 2.03 (3H, quint, J = 1.4 Hz, H-5'), 2.04 (3H, s, OCOC*H*₃), 2.04 (3H, dq, J = 8.0, 1.4 Hz, H-4'), 2.34 (3H, s, H-7), 4.99 (1H, quint, J = 1.8 Hz, H-9a), 5.11 (1H, quint, J = 1.8 Hz, H-9b), 6.21 (1H, qq, J = 8.0, 1.4 Hz, H-3'), 6.88 (1H, d, J = 1.1 Hz, H-2), 7.01 (1H, dd, J = 7.8, 1.1 Hz, H-6), 7.17 (11H, d, J = 7.8 Hz, H-5); HRCIMS *m/z* 231.1375 [M + H]⁺ (calcd for C₁₅H₁₉O₂, 231.1385).

2: IR (KBr) $\nu_{\rm max}$ 1740, 1650, 1620 cm⁻¹; EIMS *m*/*z* 288 [M]⁺, 160, 145, 83 (100), 55; ¹H NMR (CDCl₃, 400 MHz) δ 2.03 (3H, dq, *J* = 1.1, 1.1 Hz, H-5'), 2.04 (3H, s, OCOC*H*₃), 2.05 (1H, dq, *J* = 7.3, 1.1 Hz, H-4'), 2.36 (3H, s, H-7), 4.79 (2H, s, H-9), 5.23 (1H, d, *J* = 1.5 Hz, H-10a), 5.39 (1H, d, *J* = 1.5 Hz, H-10b), 6.23 (1H, qq, *J* = 7.3, 1.5 Hz, H-3'), 6.91 (1H, d, *J* = 1.1 Hz, H-2), 7.04 (1H, dd, *J* = 8.0, 1.1 Hz, H-6), 7.20 (1H, d, *J* = 8.0 Hz, H-2); HREIMS *m*/*z* 288.1333 [M]⁺ (calcd for C₁₇H₂₀O₄, 288.1362).

3: $[\alpha]_D^{24}$ -10.5 (*c* 0.57, CHCl₃); IR (KBr) ν_{max} 1740, 1650, 1630 cm⁻¹; CIMS *m/z* 291 [M + H]⁺, 231, 186, 149, 83 (100); ¹H NMR (CDCl₃, 400 MHz) δ 1.23 (3H, d, *J* = 7.0 Hz, H-10), 2.07 (3H, dq, *J* = 7.0, 1.5 Hz, H-4'), 2.07 (3H, dq, *J* = 1.5, 1.5 Hz, H-5'), 2.34 (3H, s, H-7), 3.23 (1H, sext, *J* = 7.0 Hz, H-8), 4.12 (2H, d, *J* = 7.0 Hz, H-9), 6.27 (1H, qq, *J* = 7.0, 1.0 Hz, H-3'), 6.89 (1H, d, *J* = 1.5, Hz, H-2), 7.03 (1H, dd, *J* = 8.1, 1.5 Hz, H-6), 7.19 (1H, d, *J* = 8.1 Hz, H-5); HRCIMS *m/z* 291.1598 [M + H]⁺ (calcd for C₁₇H₂₃O₄, 291.1596).

4: $[\alpha]_{D}^{23} - 32.0^{\circ}$ (*c* 1.1, CHCl₃); IR (KBr) ν_{max} 3500, 1740, 1660, 1640, 1590 cm⁻¹; CIMS *m*/*z* 263 [M + H]⁺, 261, 244, 215, 162, 145, 133, 83 (100); ¹H NMR (CDCl₃, 400 MHz) δ 2.05 (1H, dq, *J* = 1.4 Hz, H-5'), 2.08 (3H, dq, *J* = 6.0, 1.4 Hz, H-4'), 2.36 (3H, s, H-7), 2.81 (1H, d, *J* = 5.2 Hz, H-10b), 3.18 (1H, d, *J* = 5.2 Hz, H-10a), 3.84 (1H, d, *J* = 12.6 Hz, H-9b), 3.91 (1H, d, *J* = 12.6 Hz, H-9a), 6.29 (1H, qq, *J* = 6.0, 1.4 Hz, H-3'), 6.93 (1H, br s, H-2), 7.06 (1H, br d, *J* = 8.0 Hz, H-6), 7.35 (1H, d, *J* = 8.0 Hz, H-5); HRCIMS *m*/*z* 263.1281 [M + H]⁺ (calcd for C₁₅H₁₉O₄, 263.1283).

5: $[\alpha]_D^{23}$ -8.5° (*c* 0.68, CHCl₃); IR (KBr) ν_{max} 3450, 1740, 1670, 1630 cm⁻¹; CIMS *m*/*z* 321 [M + H]⁺, 320, 260, 220, 178,

161, 83 (100); ¹H NMR (CDCl₃, 600 MHz) δ 2.01 (3H, s, OCOC*H*₃), 2.04 (1H, dq, *J* = 1.5, 1.5 Hz, H-5'), 2.07 (3H, dq, *J* = 7.4, 1.5 Hz, H-4'), 2.23 (3H, s, H-7), 2.83 (1H, d, *J* = 5.5 Hz, H-10a), 3.02 (1H, d, *J* = 5.5 Hz, H-10b), 4.18 (1H, d, *J* = 12.2 Hz, H-9a), 4.54 (1H, d, *J* = 12.2, Hz, H-9b), 6.28 (1H, qq, *J* = 7.4, 1.5 Hz, H-3'), 6.86 (1H, d, *J* = 0.5 Hz, H-2), 6.89 (1H, s, H-5); HRCIMS *m*/*z* 320.1241 [M]⁺ (calcd for C₁₇H₂₀O₆, 320.1260).

6: $[\alpha]_D^{23} - 13.6^{\circ}$ (*c* 0.24, CHCl₃); IR (KBr) ν_{max} 3300, 1740, 1630, 1580 cm⁻¹; CIMS *m*/*z* 310 [M]⁺, 293, 251, 233, 222, 205, 163 (100), 145, 89; ¹H NMR (CDCl₃, 600 MHz) δ 1.15 (3H, d, *J* = 7.1 Hz, H-3'), 1.16 (3H, d, *J* = 7.1 Hz, H-4'), 1.63 (3H, s, H-10), 2.11 (3H, s, OCOC*H*₃), 2.59 (1H, sept, *J* = 7.1 Hz, H-2'), 4.27 (1H, d, *J* = 12.0 Hz, H-9a), 4.44 (1H, d, *J* = 12.0 Hz, H-9b), 5.04 (2H, s, H-7), 6.87 (1H, d, *J* = 1.7 Hz, H-2), 6.99 (1H, d, *J* = 8.0 Hz, H-5), 6.81 (1H, dd, *J* = 8.0, 1.7 Hz, H-6), 9.06 (1H, s, O*H*); HRCIMS *m*/*z* 310.1417 [M]⁺ (calcd for C₁₆H₂₂O₆, 310.1416).

7: $[\alpha]_D^{24} 0^{\circ}$ (*c* 1.71, CHCl₃); IR (KBr) ν_{max} 3300, 1630, 1570 cm⁻¹; CIMS *m*/*z* 196 [M]⁺,165, 147 (100), 135; ¹H NMR (CDCl₃, 600 MHz) δ 1.67 (3H, s, H-10), 1.93 (br s, O*H*), 2.29 (3H, s, H-7), 3.29 (3H, s, OC*H*₃), 3.56 (1H, dd, *J* = 11.6, 5.8 Hz, H-9a), 3.84 (1H, d, *J* = 11.6 Hz, H-9b), 6.68 (1H, dd, *J* = 7.7, 0.8 Hz, H-6), 6.70 (1H, d, *J* = 0.8 Hz, H-2), 6.98 (1H, d, *J* = 7.7 Hz, H-5), 8.52 (1H, s, O*H*); HRCIMS *m*/*z* 196.1101 [M]⁺ (calcd for C₁₁H₁₆O₃, 196.1099).

8: $[\alpha]_{D}^{24} 0^{\circ}$ (*c* 1.9, CHCl₃); IR (KBr) ν_{max} 3400, 1750, 1620, 1570 cm⁻¹; CIMS *m*/*z* 266 [M]⁺, 235, 165, 147 (100), 135; ¹H NMR (CDCl₃, 600 MHz) δ 1.32 (6H, d, J = 7.1 Hz, H-3', 4'), 1.66 (3H, s, H-10), 2.33 (3H, s, H-7), 2.79 (1H, sept, J = 7.1 Hz, H-2'), 3.08 (3H, s, OC*H*₃), 3.58 (1H, br d, J = 11.0 Hz, H-9a), 3.89 (1H, d, J = 11.0 Hz, H-9b), 6.78 (1H, d, J = 1.1 Hz, H-2), 7.04 (1H, dd, J = 7.9 1.1 Hz, H-6), 7.18 (1H, d, J = 7.9 Hz, H-5); HRCIMS *m*/*z* 266.1526 [M]⁺ (calcd for C₁₅H₂₂O₄, 266.1518).

9: $[\alpha]_{\rm D}{}^{20}$ 0° (*c* 1.1, CHCl₃); IR (KBr) $\nu_{\rm max}$ 3450, 1740, 1650, 1620 cm⁻¹; CIMS *m/z* 278 [M]⁺, 247, 179, 165, 147 (100); ¹H NMR (CDCl₃, 600 MHz) δ 1.60 (3H, s, H-10), 2.05 (1H, br s, O*H*), 2.06 (3H, dq, J = 1.6, 1.6 Hz, H-5'), 2.08 (3H, dq, J = 7.2, 1.6 Hz, H-4'), 2.35 (3H, s, H-7), 3.13 (3H, s, OC*H*₃), 3.60 (1H, dd, J = 11.0, 8.2 Hz, H-9a), 3.84 (1H, dd, J = 11.0, 2.7 Hz, H-9b), 6.26 (1H, qq, J = 7.2, 1.6 Hz, H-3'), 6.85 (1H, d, J = 0.8 Hz, H-2), 7.06 (1H, dd, J = 8.0, 0.8 Hz, H-5), 7.32 (1H, d, J = 8.0 Hz, H-6); HRCIMS *m/z* 278.1511 [M]⁺ (calcd for C₁₆H₂₂O₄, 278.1508).

10: $[\alpha]_{D}^{23} + 18.2^{\circ}$ (*c* 0.8, CHCl₃); IR (KBr) ν_{max} 3450, 1740, 1650, 1620 cm⁻¹; CIMS *m*/*z* 278 [M]⁺, 247 (100), 165, 147, 83; ¹H NMR (CDCl₃, 600 MHz) δ 1.60 (3H, s, H-10), 2.00 (3H, q, J = 1.1 Hz, H-4'), 2.23 (3H, q, J = 1.1, H-5'), 2.34 (3H, s, H-7), 3.15 (3H, s, OCH₃), 3.63 (1H, br d, J = 11.3, H-9a), 3.79 (1H, d, J = 11.3 Hz, H-9b), 5.91 (1H, sept, J = 1.1 Hz, H-2'), 6.84 (1H, br s, H-2), 7.04 (1H, br d, J = 8.0 Hz, H-6), 7.33 (1H, d, J = 8.0 Hz, H-5); HRCIMS *m*/*z* 278.1480 [M]⁺ (calcd for C₁₆H₂₂O₄, 278.1518).

11: $[\alpha]_{D}^{20}$ 0° (*c* 0.97, CHCl₃); IR (KBr) ν_{max} 3330, 1720, 1630, 1580 cm⁻¹; EIMS *m/z* 278 [M]⁺, 246, 165, 146 (100), 131, 83; ¹H NMR (CDCl₃, 400 MHz) δ 1.67 (3H, s, H-10), 1.88 (3H, dq, *J* = 1.5, 1.5 Hz, H-5'), 1.95 (3H, dq, *J* = 7.3, 1.5, H-4'), 2.29 (3H, s, H-7), 3.29 (3H, s, OCH₃), 4.28 (1H, d, *J* = 11.7 Hz, H-9a), 4.43 (1H, d, *J* = 11.7 Hz, H-9b), 6.07 (1H, qq, *J* = 7.3, 1.5, H-3'), 6.67 (1H, br d, *J* = 7.7 Hz, H-6), 6.70 (1H, br s, H-2), 6.93 (1H, d, *J* = 7.7, H-5), 8.51 (1H, s, OH); HREIMS *m/z* 278.1502 [M]⁺ (calcd for C₁₆H₂₂O₄, 278.1518).

12: $[\alpha]_D^{20} 0^{\circ} (c 1.1, CHCl_3)$; IR (KBr) $\nu_{max} 3330, 1740, 1630, 1580 cm^{-1}$; EIMS *m/z* 266 [M]⁺, 234, 165, 146 (100), 135, 117, 91; ¹H NMR (CDCl_3, 400 MHz) δ 1.14 (3H, d, *J* = 7.0 Hz, H-3'), 1.15 (3H, d, *J* = 7.0 Hz, H-4'), 1.63 (3H, s, H-10), 2.28 (3H, s, H-7), 2.56 (1H, sept, *J* = 7.0 Hz, H-2'), 3.27 (3H, s, OCH₃), 4.21 (1H, d, *J* = 12.0 Hz, H-9a), 4.34 (1H, d, *J* = 12.0 Hz, H-9b), 6.66 (1H, d, *J* = 7.7 Hz, H-6), 6.69 (1H, s, H-2), 6.91 (1H, d, *J* = 7.7 Hz, H-5), 8.46 (1H, s, OH); HREIMS *m/z* 266.1535 [M]⁺ (calcd for C₁₅H₂₂O₄, 266.1518).

13: $[\alpha]_D^{20} 0^{\circ}$ (*c* 0.9, CHCl₃); IR (KBr) ν_{max} 3330, 1740, 1630, 1580, 1510 cm⁻¹; CIMS *m*/*z* 280 [M]⁺, 249 (100), 179, 165, 147; ¹H NMR (CDCl₃, 600 MHz) δ 0.86 (3H, t, *J* = 7.0 Hz, H-4'), 1.12 (3H, d, *J* = 7.0 Hz, H-5'), 1.45 (1H, sept, *J* = 7.0 Hz,

H-3'a), 1.64 (3H, s, H-10), 1.65 (1H, m, H-3'b), 2.29 (3H, s, H-7), 2.40 (1H, sext, J = 7.0 Hz, H-2'), 3.28 (3H, s, OCH₃), 4.21 and 4.23 (1H, d, J = 11.6 Hz, H-9a),* 4.34 and 4.36 (1H, d, J =11.6 Hz, H-9b),* 6.70 (1H, br s, H-2), 6.67 (1H, br d, J = 7.7 Hz, H-6), 6.91(1H, d, J = 7.7 Hz, H-5), 8.48 (1H, s, OH); HRCIMS m/z 280.1688 [M]⁺ (calcd for C₁₆H₂₄O₄, 280.1675) (*due to the presence of the diastereoisomers).

14: $[\alpha]_D^{23}$ –7.9° (*c* 1.2, CHCl₃); IR (KBr) ν_{max} 3300, 1740, 1720, 1650, 1640 cm⁻¹; CIMS m/z 322 [M]⁺, 305, 244, 209, 162, 145 (100), 101, 83; ¹H NMR (CDCl₃, 400 MHz) & 1.85 (3H, dq, J = 1.5, 1.5 Hz, H-5'), 1.92 (3H, dq, J = 7.3, 1.5, H-4'), 2.07 (3H, s, OCOCH₃), 2.27 (3H, s, H-7), 4.47 (2H, s, H-9), 4.51 (1H, d, J = 12.1 Hz, H-10a), 4.54 (1H, d, J = 12.1 Hz, H-10b), 6.13 (1H, qq, J = 5.9, 1.5 Hz, H-3'), 6.65 (1H, dd, J = 8.1, 1.1 Hz, H-6), 6.70 (1H, d, J = 1.1 Hz, H-2), 6.92 (1H, d, J = 8.1 Hz, H-5), 8.77 (1H, s, OH); HRCIMS m/z 322.1391 [M]+ (calcd for C₁₇H₂₂O₆, 322.1416).

15: $[\alpha]_D^{21} - 1.6^\circ$ (*c* 1.5, CHCl₃); IR (KBr) ν_{max} 3450, 1730, 1640 cm⁻¹; CIMS *m*/*z* 322 [M]⁺, 305, 222, 209, 191, 162 (100), 145, 133, 101; ¹H NMR (CDCl₃, 400 MHz) δ 1.99 (3H, s, OCOCH₃), 2.07 (3H, dq, J = 1.5, 1.5 Hz, H-5'), 2.08 (3H, dq, J = 7.3, 1.5 Hz, H-4'), 2.34 (3H, s, H-7), 3.81 (2H, s, H-10), 4.43 (1H, d, J = 11.7 Hz, H-9a), 4.50 (1H, d, J = 11.7 Hz, H-9b), 6.33 (1H, qq, J = 7.3, 1.5 Hz, H-3'), 6.86 (1H, d, J = 1.1 Hz, H-2), 7.07 (1H, dd, J = 8.0, 1.1 Hz, H-6), 7.56 (1H, d, J = 8.0 Hz, H-5); HRCIMS m/z 322.1391 [M]⁺ (calcd for C₁₇H₂₂O₆, 322.1416).

16: $[\alpha]_D^{21} - 13.1^\circ$ (*c* 0.64, CHCl₃); IR (KBr) ν_{max} 3300, 1710, 1620, 1590 cm⁻¹; CIMS m/z 181 [M + H]⁺, 179, 163, 161, 135 (100); ¹H NMR (CDCl₃, 400 MHz) δ 2.11 (3H, s, H-10), 2.30 (3H, s, H-7), 5.17 (1H, s, H-8), 6.68 (1H, s, H-2), 6.75 (1H, d, J = 7.7 Hz, H-6), 7.10 (1H, d, J = 7.7 Hz, H-5); HRCIMS m/z181.0854 $[M + H]^+$ (calcd for $C_{10}H_{13}O_3$, 181.0865).

Preparation of MOM-Protected Derivative of 5. A solution of compound 5 (3 mg) in CH₂Cl₂ (0.3 mL) was treated with *i*Pr₂NEt (0.1 mL) and CH₃OCH₂Cl (0.1 mL) at room temperature for 5 h. A saturated NaHCO₃ solution was added, and the mixture was extracted with CH₂Cl₂. The organic phases were washed with brine, dried over anhydrous MgSO₄, and evaporated to afford a crude product (9.5 mg), which was purified by HPLC (hexane-AcOEt 15%) to give pure 5a (1.6 mg).

5a: IR (KBr) $\nu_{\rm max}$ 1740, 1640 cm⁻¹; CIMS m/z 364 [M]⁺ 304, 273, 264, 243, 222, 205, 191, 160, 83 (100); ¹H NMR (CDCl₃, 400 MHz) δ 2.02 (3H, s, OCOCH₃), 2.07 (3H, dq, J = 1.5, 1.5Hz, H-5'), 2.08 (3H, dq, J = 7.4, 1.5 Hz, H-4'), 2.24 (3H, d, J = 0.6 Hz, H-7), 2.84 (1H, d, J = 5.2 Hz, H-10a), 3.02 (1H, d, J =5.2 Hz, H-10b), 3.49 (3H, s, OCH₃), 4.18 (1H, d, J = 12.3 Hz, H-9a), 4.52 (1H, d, J = 12.3 Hz, H-9b), 5.17 (1H, d, J = 6.6 Hz, OC H_2 O), 5.21 (1H, d, J = 6.6 Hz, OC H_2 O), 6.28 (1H, qq, J = 7.4, 1.5 Hz, H-3'), 6.90 (1H, d, J = 0.6 Hz, H-2), 7.14 (1H, s, H-5); HRCIMS m/z 365.1587 [M + H]⁺ (calcd for C₁₉H₂₅O₇, 365.1601).

Acknowledgment. We thank Dr. M. Tanaka and Miss Y. Okamoto (this university) for measurement of the 600 MHz NMR and all MS spectra, respectively. The identification of the plant was made by Dr. T. Kawahara, Hokkaido Research Center of Forestry and Forest Products Research Institute, Ministry of Agriculture, Forestry and Fisheries, Japan, to whom many thanks are due.

References and Notes

- (1) Yoshizaki, M.; Suzuki, H.; Sano, K.; Kimura, K.; Namba, T. Yakugaku Zassi, 1974, 94, 338-342, and references therein.
- (2) Haruna, M.; Sakakibara, Y.; Ito, K. Chem. Pharm. Bull. 1986, 34, 5157 - 5160
- (3) Liu, K.; Roeder, E.; Chen, H. L.; Xiu, X. J. Phytochemistry 1992, 31, 2573-2574.
- (4) Bohlmann, F.; Mahanta, P. K.; Suwita, A.; Suwita, A.; Natu, A. A.; Zdero, C.; Dorner, W.; Ehlers, D.; Grenz, M. Phytochemistry 1977, 16, 1973-1981.
- (5) Bohlmann, F.; Jakupovic, J.; Lonitz, M. Chem. Ber. 1977, 110, 301-314.
- (6) Monache, G. D.; Monache, F. D.; Becerra, J.; Silva, M.; Menichini, F. *Phytochemistry* 1984, 23, 1947–1950.
- (7) Wu, T. S.; Niwa, M.; Furukawa, H.; Kuoh, C. S. Chem. Pharm. Bull. 1985, 33, 4005-4006.
- Trang, N. D.; Wanner, M. J.; Koomen, G. J.; Dung, N. X. *Planta Med.* **1993**, *59*, 480–481. (8)
- (9)(a) Tori, M.; Kawahara, M.; Sono, M. Tetrahdron Lett. 1997, 38, 1965-1968. (b) Tori, M.; Kawahara, M.; Sono, M. Phytochemistry 1998, 47, 401-409.
- (10) Tori, M.; Shiotani, Y.; Tanaka, M.; Nakashima, K.; Sono, M. *Tetrahedron Lett.* **2000**, *41*, 1797–1799.
 (11) Tori, M.; Takeichi, Y.; Nakashima, K.; Sono, M. *Heterocycles* **2000**, *52*, 1075–1078.
- (12) Tori, M.; Katto, A.; Sono, M. Phytochemistry 1999, 52, 487-493.
- (13) Joseph-Nathan, P.; Wesener, J. R.; Günter, H. Org. Magn. Reson. 1984, 22, 190-191.
- (14) The protons at δ 5.17 and 5.21 were assigned to the methylene protons of the MOM group, because they had an NOE with the methoxyl group. The proton H-5 shifted 0.25 ppm downfield in compound 5a. Since other protons than H-5 appeared almost in the same region as that of compound 5 in the ¹H NMR spectrum, no rearrangement record deviced deviced devices.
- (15) (a) Bohlmann, F.; Kramp, W.; Gupta, R. K.; King, R. M.; Robinson, H. *Phytochemistry* 1981, *20*, 2375–2378. (b) de Pascual-T, J.; Bellido, I. S.; Torres, C.; Sastre, B. A.; Grande, M. *Phytochemsitry* 1981, *20*, 163-165. (c) Pérez, A. L.; De Vivar, A. R. Phytochemistry 1994, 36, 1081-1082.
- (16) Bohlmann, F.; Zdero, C. Phytochemistry 1977, 16, 1243-1245
- (17) (a) Bohlmann, F.; Zdero, C. *Phytochemistry* 1977, *16*, 1773–1776. (b) Bohlmann, F.; Dhar, A. K.; Ahmed, M. *Phytochemistry* 1980, *19*, 1850 - 1851.
- (a) Damodaran, N. P.; Dev, S. Tetrahedron 1968, 24, 4113-4122. (b) Warnhoff, E. W.; Srinivasan, V. Can. J. Chem. 1973, 51, 3955-3962.

NP0101191